RE: AN’s options19 Jan 2022 15:25
Long term inventive plan options
Cut from the latest financial report on angleplc.com p54
"The performance conditions for the LTIP Options relate to i) the Company achieving FDA clearance for its Parsortix system and ii) the compound annual growth rate
(CAGR) of the share price over the three-year performance period. The mid-market share price on 25 September 2020 was £0.53 per Ordinary share. As different
levels of performance are achieved the number of shares that vest increases up to a maximum, as set out below:"
The award for submitting FDA was not for share options but for a 60% bonus salary